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Background: Syringe sharing continues to be a major driver of the HIV pandemic. In light of efforts to enhance
access to sterile syringes and promote secondary prevention among HIV-positive individuals, we sought to identify
the prevalence and correlates of used syringe lending among self-reported HIV-positive people who inject drugs
(PWID) in Bangkok, Thailand.
Findings: We used bivariable statistics to examine factors associated with self-reported syringe lending among
self-reported HIV-positive PWID participating in the Mitsampan Community Research Project, a serial cross-sectional
study of PWID in Bangkok, between June 2009 and October 2011. In total, 127 individuals were eligible for this
analysis, including 25 (19.7 %) women. Twenty-one (16.5 %) participants reported syringe lending in the prior
6 months. Factors significantly associated with syringe lending included daily methamphetamine injection (odds
ratio (OR) = 10.2, 95 % CI, 2.1–53.6), daily midazolam injection (OR = 3.1, 95 % CI, 1.1–8.7), use of drugs in combination
(OR = 4.5, 95 % CI, 1.0–41.6), injecting with others on a frequent basis (OR = 4.25, 95 % CI, 1.3–18.3), and not receiving
antiretroviral therapy (OR = 2.9, 95 % CI, 1.1–7.9).
Conclusions: A high prevalence of syringe lending was observed among self-reported HIV-positive PWID in Bangkok,
which was associated with high intensity drug use, polysubstance use, and frequently injecting with others. It is
particularly concerning that individuals who lent syringes were more likely to be untreated for HIV disease given the
known benefits of antiretroviral provision on the prevention of HIV transmission. These findings underscore the need
to expand access to sterile syringes and HIV treatment among HIV-positive PWID in Thailand.
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Syringe sharing among people who inject drugs (PWID)
continues to be a major driver of the global HIV/AIDS
pandemic. Globally, an estimated 1 in 10 new HIV infec-
tions is caused by injection drug use [1]. The World
Health Organization and other United Nations agencies
consider needle and syringe programs (NSPs) to be a* Correspondence: uhri-tk@cfenet.ubc.ca
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PWID [2]. However, in Thailand, despite endorsement
of NSPs by public health authorities, such programs
continue to be regarded as illegal [3], resulting in NSP
coverage as low as <1 % among PWID in Thailand [4].
Despite the legal controversy regarding NSPs, efforts are
currently underway to enhance access to sterile syringes
and promote secondary prevention among HIV-positive
PWID in Thailand, including the provision of sterile syrin-
ges within drop-in centers for PWID that are operated by
civil society and international organizations [5]. In light of
these efforts, we investigated the prevalence and correlatesicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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of HIV-positive PWID in Bangkok, Thailand.
Methods
The Mitsampan Community Research Project is a col-
laborative research project involving the Mitsampan
Harm Reduction Center (Bangkok, Thailand), the Thai
AIDS Treatment Action Group (Bangkok, Thailand),
Chulalongkorn University (Bangkok, Thailand), and the
British Columbia Centre for Excellence in HIV/AIDS/
University of British Columbia (Vancouver, Canada). Be-
tween June 2009 and October 2011, the research part-
ners undertook a serial cross-sectional study involving
650 unique community-recruited PWID. Potential par-
ticipants were recruited through peer outreach and word
of mouth and were invited to attend the Mitsampan
Harm Reduction Center or O-Zone House (local drop-in
centers for people who use drugs) to be part of the
study. Adults residing in Bangkok or adjacent provinces
who had injected drug(s) in the previous 6 months were
eligible for participation in the study. All participants
provided oral informed consent and completed an
interviewer-administered questionnaire eliciting demo-
graphic data as well as information about drug use pat-
terns, HIV risk behavior, and experiences with healthcare
services. Participants received a stipend of 350 Thai Baht
(approximately $11 USD) upon completion of the ques-
tionnaire. The study was approved by the research ethics
boards at Chulalongkorn University and the University of
British Columbia.
The present analysis was restricted to PWID who re-
ported being HIV-positive. The primary outcome of
interest was reporting syringe lending in the 6 months
prior to the time of interview, as defined by responding
“Yes” to the question: “Have you lent your used needles/
syringes to someone else in the last six months?” We
compared the demographic, behavioral, and social/struc-
tural characteristics of PWID who did and did not re-
port syringe lending using Pearson’s X2 test and Fisher’s
exact test (when one or more cells contained values less
than or equal to five). Variables considered included the
following: median age (<38 years vs. ≥38 years), gender
(male vs. female), education level (<secondary education
vs. ≥secondary education), incarceration (yes vs. no), fre-
quent heroin injection (≥daily vs. <daily), frequent meth-
amphetamine injection (≥daily vs. <daily), frequent
midazolam injection (≥daily vs. <daily), binge drug use
(yes vs. no), use of drugs in combination (yes vs. no),
injecting with others on a frequent basis (≥25 % of the
time vs. <25 % of the time), enrollment in voluntary
drug treatment (including methadone treatment) (yes vs.
no), reporting difficulty accessing sterile syringes (yes
vs. no), and receiving antiretroviral therapy (ART) at
the time of interview (receiving vs. not receiving). Allbehavioral variables refer to the previous 6 months un-
less otherwise indicated. All p values were two-sided.
Results
A total of 650 unique individuals were seen during the
study period, of which 127 (19.5 %) HIV-positive indi-
viduals with complete data were eligible for this study.
Among the 127 individuals included in this study, 25
(19.7 %) were female. The median age was 38 years
(interquartile range, 34–43 years). In total, 21 (16.5 %)
participants reported that they had lent a used syringe to
another person within the 6 months prior to their inter-
view. As indicated in Table 1, factors significantly and
positively associated with syringe lending in bivariable
analyses included the following: daily methamphetamine
injection (odds ratio (OR) = 10.20, 95 % CI, 2.08–53.60),
daily midazolam injection (OR = 3.14, 95 % CI, 1.13–
8.72), use of drugs in combination (OR = 4.49, 95 % CI,
0.98–41.60), injecting with others on a frequent basis
(OR = 4.25, 95 % CI, 1.26–18.30), and not receiving ART
(OR = 2.93, 95 % CI, 1.09–7.86).
Discussion
A high prevalence of used syringe lending was observed
among our sample of HIV-positive PWID in Bangkok,
with 16.5 % of participants reporting syringe lending in
the past 6 months. Individuals who reported syringe
lending were more likely to report high intensity drug
use (i.e., daily injection of methamphetamine or midazo-
lam), polysubstance use, frequently injecting with others,
and not receiving ART.
It is particularly concerning that individuals who lent
syringes were more likely to be untreated for HIV, given
the known benefits of ART in preventing HIV transmis-
sion [6]. This finding may suggest that individuals re-
ceiving ART may have greater access to NSPs and/or
education on safer injecting practices secondary to their
engagement in HIV care, compared to PWID not receiv-
ing ART, who may lack access to such education or ser-
vices. Furthermore, HIV testing rates remain low in the
Asia-Pacific region, with approximately 20 % of PWID
having been previously tested [7] and approximately
13 % of PWID avoiding HIV testing in one study in
Thailand [8]. Similarly, PWID in Thailand demonstrate
considerably low rates of ART coverage, with only 2 % of
HIV-positive PWID estimated to have ever accessed
ART [4], compared to a reported ART coverage rate of
65 % among all eligible people living with HIV in
Thailand [9]. Given Thailand’s system of universal
healthcare that provides ART for free or at a reduced
cost [10], the comparatively lower rates of ART uptake
among PWID may be attributable to the Thai govern-
ment’s aggressive drug law enforcement strategies that
may serve as barriers or deterrents for PWID to access
Table 1 Bivariable analysis of factors associated with syringe lending among a community-recruited sample of
HIV-positive PWID in Bangkok, Thailand (n = 127)
Characteristic Syringe lendinga Odds ratio (95 % CI) p value
Yes 21 (16.5 %) No 106 (83.5 %)
Age
<38 years 11 (52.4) 52 (49.1) 1.14 (0.45–2.92) 0.781
≥38 years 10 (47.6) 54 (50.9)
Gender
Male 19 (90.5) 83 (78.3) 0.38 (0.04–1.78) 0.246
Female 2 (9.5) 23 (21.7)
Education level
<Secondary education 11 (52.4) 42 (39.6) 1.68 (0.65–4.29) 0.279
≥Secondary education 10 (47.6) 64 (60.4)
Incarcerationa
Yes 3 (14.3) 13 (12.3) 1.19 (0.20–4.99) 0.728
No 18 (85.7) 93 (87.7)
Heroin injection frequencya
≥Daily 2 (9.5) 15 (14.2) 0.64 (0.07–3.14) 0.736
<Daily 19 (90.5) 91 (85.8)
Methamphetamine injection frequencya
≥Daily 6 (28.6) 4 (3.8) 10.20 (2.08–53.59) 0.001
<Daily 15 (71.4) 102 (96.2)
Midazolam injection frequencya
≥Daily 15 (71.4) 47 (44.3) 3.14 (1.13–8.72) 0.023
<Daily 6 (28.6) 59 (55.7)
Binge drug usea
Yes 11 (52.4) 34 (32.1) 2.33 (0.90–6.01) 0.076
No 10 (47.6) 72 (67.9)
Use of drugs in combinationa
Yes 19 (90.5) 72 (67.9) 4.49 (0.98–41.55) 0.037
No 2 (9.5) 34 (32.1)
Injected with others on a frequent basisa
≥25 % of the time 17 (81.0) 53 (50.0) 4.25 (1.26–18.33) 0.015
<25 % of the time 4 (19.0) 53 (50.0)
Enrolled in voluntary drug treatment (including methadone)a
Yes 8 (38.1) 38 (35.8) 1.10 (0.42–2.89) 0.845
No 13 (61.9) 68 (64.2)
Difficulty accessing sterile syringesa
Yes 0 (0.0) 5 (4.7) 0.590
No 21 (100.0) 101 (95.3)
Receiving antiretroviral therapyb
Receiving 7 (33.3) 63 (59.4)
Not receiving 14 (66.7) 43 (40.6) 2.93 (1.09–7.86) 0.028
PWID people who inject drugs
aDenotes events/activities during the 6 months prior to the interview
bDenotes events/activities at the time of the interview
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receiving ART among PWID who lent syringes in this
study may suggest that aggressive enforcement may be
shaping HIV risk behavior and ART uptake by discour-
aging access to HIV treatment and prevention programs.
Therefore, targeted efforts to reduce the public health
burden of aggressive drug law enforcement strategies
(e.g., compulsory drug detention) within this setting
should occur alongside initiatives to scale up evidence-
based public health interventions including HIV testing,
ART, peer-based HIV education, and NSPs, as described
below [13]. Strategies to address these gaps are currently
underway in Thailand, including plans to provide ART
irrespective of CD4 count and harmonize health insur-
ance schemes for greater service deliver efficiency [14].
Other interventions to enhance access to and implemen-
tation of early ART initiation should be also supported
for HIV-positive PWID in Thailand. Finally, given the
high prevalence (85–90 %) of HIV and hepatitis C
(HCV) co-infection among PWID in Thailand [15, 16],
as well as the greater transmissibility of HCV compared
to HIV, these findings warrant further research on syr-
inge lending behaviors among HCV-infected PWID and
increased HCV testing, treatment, and education for
PWID in Thailand.
The associations between syringe lending and high in-
tensity drug use are consistent with previous literature
on PWID in Thailand. Specifically, the association be-
tween daily methamphetamine injection and syringe
lending in this study is consistent with a 2011 study that
found that frequent methamphetamine injection was
positively and independently associated with syringe
sharing among Thai PWID [17]. Additionally, previous
studies have found associations between syringe sharing
and polysubstance use [18]. Given that midazolam is
commonly used in combination with other drugs, the
observed association between daily midazolam injection
and syringe lending in this study may reflect the high
prevalence of polysubstance use among midazolam in-
jectors in Bangkok [19, 20]. Finally, our finding that syr-
inge lending was associated with frequent injection with
others complements previous associations found be-
tween frequent injection with others and syringe bor-
rowing among Thai PWID [21].
These findings add to the growing body of literature
pointing to the high prevalence of risk behaviors for
HIV and other infectious diseases (e.g., hepatitis C)
among Thai PWID and the importance of harm reduc-
tion programs as an essential response to these epi-
demics [22]. In particular, NSPs have been shown to
dramatically reduce the prevalence of high-risk injection
behaviors, as evidenced by a decrease in syringe sharing
among PWID by more than 38 % due to the distribution
of sterile injection equipment in one Canadian setting[23]. Furthermore, NSPs have been shown to prevent
HIV and hepatitis C transmission among PWID [24].
Previous studies have highlighted the various difficulties
that Thai PWID face in accessing sterile syringes, in-
cluding distance from NSPs, limited pharmacy hours,
and being refused syringes at pharmacies [21]. In order
to reduce the harms associated with injection drug use,
particularly the risk of HIV and other infectious disease
transmission, urgent action is needed to address these
barriers and expand access to NSPs in Thailand.
This study has several limitations. First, due to the
cross-sectional study design, we were unable to deter-
mine temporal relationships between the explanatory
variables and the outcome. Thus, we are unable to infer
causation from this observational study. Additionally, be-
cause we observed only 21 participants reporting syringe
lending, we were unable to conduct multivariable analyses
to examine the independent relationships between the ex-
planatory variables and the outcome. Therefore, the asso-
ciations observed in the present study should be further
examined through multivariable, longitudinal analyses
with a larger sample size. Third, the data collected were
self-reported, including HIV serostatus, and may be sub-
jected to reporting biases such as socially desirable report-
ing and recall bias. However, self-reported data are
commonly used in observational studies involving PWID
and have been repeatedly found to be valid [25, 26].
Nevertheless, it is possible that the use of self-reported
serostatus in this study may confound the association be-
tween syringe lending and enrolment in antiretroviral
therapy, such that individuals who are on ART may more
accurately report their HIV serostatus compared to indi-
viduals not receiving ART, who may not have been for-
mally tested for HIV. Fourth, given that the study sample
was not randomly selected, the study findings may not be
generalizable to Thai PWID or PWID in other settings. Fi-
nally, we did not collect data on number of injection part-
ners; however, given past research highlighting the
potential influence of social networks on syringe sharing
behaviors among PWID [24, 27], this is an area that would
benefit from further investigation.
In sum, 16.5 % of our sample of HIV-positive PWID in
Bangkok reported used syringe lending in the 6 months
prior to being interviewed. This high-risk behavior was
associated with high intensity drug use, polysubstance
use, injecting with others on a frequent basis, and not re-
ceiving ART. These findings emphasize the need to expand
evidence-based public health interventions for HIV-positive
PWID in Thailand, particularly through the expansion of
early ART, NSPs, and peer-based HIV education.
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